Ralph Zinner

Ralph G. Zinner, MD

Contact Dr. Zinner

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874
(215) 503-2715 fax

Most Recent Peer-reviewed Publications

  1. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
  2. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
  3. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
  4. Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
  5. Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes
  6. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: Update of the MD Anderson Cancer Center experience
  7. Multiplex KRASG12/G13mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction
  8. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials
  9. Activity of c-Met/ALK inhibitor crizotinib and multi-kinase VEGF inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor harboring EWSR1-CREB1 fusion
  10. TP53 alterations correlate with response to VEGF/VEGFR inhibitors: Implications for targeted therapeutics
  11. Cancer therapy directed by comprehensive genomic profiling: A single center study
  12. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: Phase I trial experience
  13. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system
  14. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
  15. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
  16. Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)
  17. Systemic therapy for echinoderm microtubule-associated proteinlike 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases
  18. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
  19. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response
  20. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors